Drug Trial Radar · NCT00982904
Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the Fexinidazole
Last checked: Nov 20, 2026Latest source record: Apr 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
108
Actual
Start
Sep 2009
Primary completion
Sep 2010
Study completion Oct 2010
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sanofi
- First posted
- Sep 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is aimed at assessing the tolerability and pharmacokinetic parameters of the fexinidazole in healthy volunteers. In animal models of both acute and chronic experimental Trypanosomiasis infections, fexinidazole shows highly promising efficacy.
Conditions
- Human African Trypanosomiasis
Interventions
Fexinidazole/PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurence of adverse events (AEs)Time frame: 8 to 37 days, depending on the part of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SGS Aster
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.